

# Target patient populations

2025


 **NOVARTIS** | Reimagining Medicine



# Disclaimer

This presentation includes data from both Novartis published studies as well as third-party sources, as referenced throughout. Such third-party data may include certain assumptions, is included for informational purposes only and has not been independently verified by Novartis for accuracy or completeness. As a result, no representation or warranty, express or implied, is made as to the accuracy, completeness, or correctness of this information.


# Cardiovascular, renal and metabolic



# Chronic heart failure

## Prevalence

Thousand patients




Sources: Cardiovascular Resource Group, IQVIA, Novartis. Data for the year 2025. Epidemiology numbers include patients without access.

# Atherosclerotic cardiovascular disease

## Prevalence

Thousand patients




LLT – Lipid lowering therapy. Lp(a) – Lipoprotein(a). Diagnosed refers to patients with established ASCVD. Treated refers to treatment with statin and/or ezetimibe. Advanced LLT include PCSK9i mAbs, Leqvio, bempedoic acid. Elevated Lp(a) goals based on lower of local guidelines and real-world evidence. Guidelines: Elevated Lp(a) if  $\geq 70$  mg/dl, in JP/ES  $\geq 90$  mg/dl. Real-world data: China/Japan  $\geq 30$  mg/dl. Sources: Clarivate/DRG, AHA, ACC, Adelphi/JAMA, IQVIA, INSEE, LAAD, Novartis. Data for year 2025. Epidemiology numbers include patients without access.

# IgA nephropathy

## Prevalence

Thousand patients




Persistent proteinuria refers to >1g/day and GFR >30 ml/min. Treated includes ACEi, ARBs, SGLT2i, corticosteroids, tonsillectomy (JP). Sources: CDA, Clarivate, Opti-Brand PMR, Adelphi, ZS conjoint 2024, Spherix. Data for year 2025. Epidemiology numbers include patients without access.

# Complement 3 glomerulopathy

## Prevalence

Patients



Persistent proteinuria refers to >1g/day and GFR >30 ml/min. Treated includes ACEi, ARBs, SGLT2i, corticosteroids, MMF. Sources: CDA, Clarivate, Opti-Brand PMR, Adelphi, Putnam Conjoint 2024. Data for year 2025. Epidemiology numbers include patients without access.


# Immunology



# Psoriasis

## Prevalence

Thousand patients




Moderate-severe defined as PASI > 10 or BSA > 10 AND DLQI > 10. Prevalence and Diagnosed data assumed to be the same for China.

For China M-S BSA>3. Systemic treated includes orals (including retinoids, immunosuppressants, PDE4s, TYK2s, JAKs) and biologics but excludes topicals. Source: DRG, IQVIA, National Psoriasis Foundation, Novartis. Data for year 2025. Epidemiology numbers include patients without access.

# Psoriatic arthritis

## Prevalence

Thousand patients




Systemic treated includes treatment with DMARDs, orals and biologics. Source: DRG, IQVIA, APLD, Novartis. Data for year 2025. Epidemiology numbers include patients without access.

# Axial spondyloarthritis

## Prevalence

Thousand patients




Systemic treated includes treatment with DMARDs, orals and biologics. Source: DRG, IQVIA, Novartis. Data for year 2025. Epidemiology numbers include patients without access.

# Hidradenitis suppurativa

## Prevalence

Thousand patients




Moderate-to-severe includes Hurley State II and III. Treated refers to treatment with topicals, antibiotics, anti-androgens, DMARDs biologics and surgery. Source: IQVIA, DRG, Novartis. Data for year 2025. Epidemiology numbers include patients without access.

# Chronic spontaneous urticaria

## Prevalence

Thousand patients




Treated refers to adults with antihistamines and biologics. Uncontrolled despite treatment with H1, H2 antihistamines incl. dose escalation. Source: GA2LEN, World Bank, Novartis. Data for year 2025. Epidemiology numbers include patients without access.

# Chronic inducible urticaria

## Prevalence

Thousand patients




Diagnosed refers to adults. Inadequately controlled refers to patients showing CINDU symptoms despite treatment with SoC. Source: US 2024 CENSUS, Market Map, Compare Study, Novartis. Data for year 2025. Epidemiology numbers include patients without access.

# Sjögren's

## Prevalence

Thousand patients




Prevalence assumes primary Sjogrens patients only. Source: Kantar Health, DRG, Evaluate Pharma, US demand study, Novartis. Data for year 2025. Epidemiology numbers include patients without access.

# Systemic Lupus Erythematosus

## Prevalence

Thousand patients




Source: DRG, CPO, Novartis. Data for year 2025. Epidemiology numbers include patients without access.

# Lupus Nephritis

## Prevalence

Thousand patients



Source: DRG, CPO Novartis. Data for year 2025. Epidemiology numbers include patients without access.


# Neuroscience



# Multiple sclerosis

## Prevalence

Thousand patients




DMT – Disease modifying therapy. RMS – Relapsing multiple sclerosis. RMS includes clinically isolated syndrome, relapsing-remitting and active secondary progressive forms of multiple sclerosis. Sources: Global Disease Burden (IHME Portal), Spherix Chart Study, MSIF, IQVIA, Stethos, DRG, Novartis. Data for year 2025. Epidemiology numbers include patients without access.

# Spinal muscular atrophy



## Incidence

Patients



## Prevalence

Patients



GTx – Gene therapy. Eligible for GTx (incidence) excludes share with elevated anti-AAV9 antibody titers. Eligible for GTx (prevalence) defined as patients above 2 years, removing IV Tx pts, and not adjusted for AAV9 eligibility. Source: CDC, CureSMA, NIH, Novartis. Data for year 2025. Epidemiology numbers include patients without access.


# Oncology



# HR+/HER2- breast cancer

## Incidence

Thousand patients



Incidence includes de novo patients with no prior history of breast cancer and recurrent patients who had eBC. Epidemiology numbers include patients without access.


Treated refers to treatment with systemic therapy.

Sources: Cerner Enviza 2025, DRG, Novartis. Data for year 2025.

# Prostate cancer

## Incidence

Thousand patients




Sources: Oracle, Novartis, National Office for Cancer Prevention and Control, China. Data for year 2025. Epidemiology numbers include patients without access.

# Chronic myeloid leukemia

## Prevalence

Thousand patients




Prevalence includes 90%-95% Ph+CML-CP and 5%-10% acute phase depending on geographies. Treated refers to treatment with 1st and 2nd generation TKIs. Sources: Kantar, CancerMpact 2025, Novartis. Data for year 2025. Epidemiology numbers include patients without access.

# Immune Thrombocytopenia

## Incidence

Thousand patients




Sources: DRG, Novartis. Data for year 2025. Epidemiology numbers include patients without access.

# Warm autoimmune hemolytic anemia

## Incidence

Thousand patients




Sources: ORPHANET, NORD, Pubmed. Data for year 2025. Epidemiology numbers include patients without access.

# Paroxysmal nocturnal hemoglobinuria

## Prevalence

Thousand patients



Prevalence includes adults only. Treated refers to complemented treated patients with 90% access applied for Japan and China markets. For EU5 markets, 100% access has been assumed. US data includes patients treated with complement therapy and include patients without access. Sources: DRG, Evaluate, Novartis. Data for year 2025.

**Thank you**

 **NOVARTIS** | Reimagining Medicine

